ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of -$170.80 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-20.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2018-02-20
- ELI LILLY AND COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2017-12-31 was -$21.10M, a 124.34% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2017-09-30 was -$33.90M.
- ELI LILLY AND COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2017-06-30 was -$86.10M, a 431.15% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2017-03-31 was -$29.70M.
- ELI LILLY AND COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2017 was -$170.80M, a 341.93% decline from fiscal 2016.
- ELI LILLY AND COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2016 was $70.60M, a 3430.00% increase from fiscal 2015.
- ELI LILLY AND COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2015 was $2.00M.
- ELI LILLY AND COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2014 was $0.00.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month as first filed | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month as first filed | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month |
|---|---|---|---|---|---|---|
| 2017-12-31 | -$21.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | -$55.00M derived: sum of 2 quarters · filed 2018-02-20 | -$141.10M derived: sum of 3 quarters · filed 2018-02-20 | -$170.80M 10-K · filed 2018-02-20 | ||
| 2017-09-30 | -$33.90M 10-Q · filed 2017-10-27 | -$120.00M derived: sum of 2 quarters · filed 2017-10-27 | -$149.70M 10-Q · filed 2017-10-27 | -$63.00M derived: sum of 4 quarters · filed 2018-02-20 | ||
| 2017-06-30 | -$86.10M 10-Q · filed 2017-07-28 | -$115.80M 10-Q · filed 2017-07-28 | -$29.10M derived: sum of 3 quarters · filed 2018-02-20 | -$43.50M derived: sum of 4 quarters · filed 2018-02-20 | ||
| 2017-03-31 | -$29.70M 10-Q · filed 2017-05-01 | $57.00M derived: sum of 2 quarters · filed 2018-02-20 | $42.60M derived: sum of 3 quarters · filed 2018-02-20 | $68.60M derived: sum of 4 quarters · filed 2018-02-20 | ||
| 2016-12-31 | $86.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $72.30M derived: sum of 2 quarters · filed 2018-02-20 | $98.30M derived: sum of 3 quarters · filed 2018-02-20 | $70.60M 10-K · filed 2018-02-20 | ||
| 2016-09-30 | -$14.40M 10-Q · filed 2017-10-27 | $11.60M derived: sum of 2 quarters · filed 2017-10-27 | -$16.10M 10-Q · filed 2017-10-27 | -$31.80M derived: sum of 4 quarters · filed 2018-02-20 | ||
| 2016-06-30 | $26.00M 10-Q · filed 2017-07-28 | -$1.70M 10-Q · filed 2017-07-28 | -$17.40M derived: sum of 3 quarters · filed 2018-02-20 | -$11.50M derived: sum of 4 quarters · filed 2018-02-20 | ||
| 2016-03-31 | -$27.70M 10-Q · filed 2017-05-01 | -$43.40M derived: sum of 2 quarters · filed 2018-02-20 | -$37.50M derived: sum of 3 quarters · filed 2018-02-20 | -$49.30M derived: sum of 4 quarters · filed 2018-02-20 | ||
| 2015-12-31 | -$15.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | -$9.80M derived: sum of 2 quarters · filed 2018-02-20 | -$21.60M derived: sum of 3 quarters · filed 2018-02-20 | $2.00M 10-K · filed 2018-02-20 | ||
| 2015-09-30 | $5.90M 10-Q · filed 2016-10-28 | -$5.90M derived: sum of 2 quarters · filed 2016-10-28 | $17.70M 10-Q · filed 2016-10-28 | -$5.90M derived: sum of 4 quarters · filed 2017-02-21 | ||
| 2015-06-30 | -$11.80M 10-Q · filed 2016-07-28 | $11.80M 10-Q · filed 2015-07-30 | -$11.80M 10-Q · filed 2016-07-28 | $11.80M 10-Q · filed 2015-07-30 | -$11.80M derived: sum of 3 quarters · filed 2017-02-21 | -$11.80M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $0.00 10-Q · filed 2016-04-29 | $0.00 derived: sum of 2 quarters · filed 2017-02-21 | $0.00 derived: sum of 3 quarters · filed 2017-02-21 | $0.00 derived: sum of 4 quarters · filed 2017-02-21 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $0.00 derived: sum of 2 quarters · filed 2017-02-21 | $0.00 derived: sum of 3 quarters · filed 2017-02-21 | $0.00 10-K · filed 2017-02-21 | ||
| 2014-09-30 | $0.00 10-Q · filed 2015-10-30 | $0.00 derived: sum of 2 quarters · filed 2015-10-30 | $0.00 10-Q · filed 2015-10-30 | |||
| 2014-06-30 | $0.00 10-Q · filed 2015-07-30 | $0.00 10-Q · filed 2015-07-30 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |